Trial News & Events
Top Highlights from the 30th Anniversary NEALS 2025 Annual Meeting
This year’s event brought together over 1,000 researchers, clinicians, industry partners, non-profit collaborators, and people living with ALS to share knowledge, collaborate, and honor the strength of our community.
AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS)
- Phase 2 of AP-101 in sporadic ALS and mutant SOD1-ALS met its primary safety and tolerability endpoint
Sign Up Today! Bike the US for ALS- NEALS Ride
Bike the US for ALS – 30th Anniversary Ride
Ride. Support. Make an Impact.
We invite you to join us for a special fundraising ride as we commemorate 30 years of advancing ALS research and care through NEALS.
🚴♂️ September 18–24, 2025
📍 Route: GAP and C&O Trail (Pittsburgh, PA → Washington, D.C.)
🎯 Fundraising Goal: $5,000 per rider
Qalsody Conditionally Approved in Canada for ALS Linked to SOD1 Gene Mutations
QALSODY™ (tofersen injection) Receives Conditional Marketing Authorization from Health Canada as the First ALS Treatment Targeting a Genetic Cause
